Important Information for Regeneron Pharmaceuticals Investors: Rosen Law Firm Announces Securities Class Action Lawsuit
New York, NY – In a recent press release dated January 22, 2025, Rosen Law Firm, a leading investor rights law firm, announced the filing of a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN) on behalf of purchasers of the company’s securities between November 2, 2023, and October 30, 2024. The lawsuit alleges that the company made false and/or misleading statements and/or failed to disclose material information during the Class Period.
Background
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for various diseases, including cancer, cardiovascular diseases, and inflammatory and neurological conditions. The company’s flagship product, Eylea, is used to treat various eye diseases, including wet age-related macular degeneration and diabetic macular edema.
Allegations
The complaint alleges that Regeneron and certain of its executives made false and/or misleading statements and/or failed to disclose material information during the Class Period. Specifically, the complaint alleges that the defendants failed to disclose that:
- Regeneron’s Eylea was experiencing decreased demand due to competition from cheaper alternatives;
- The company’s sales growth was slowing down;
- Regeneron was facing increased regulatory scrutiny regarding its pricing practices;
- The company’s pipeline was not as strong as represented;
Impact on Individual Investors
If you purchased Regeneron securities during the Class Period, you may be eligible to participate in the securities class action lawsuit. The lead plaintiff deadline is March 10, 2025. If you wish to serve as lead plaintiff, you must meet certain legal requirements and must file a motion with the court before the lead plaintiff deadline. If you do not wish to serve as lead plaintiff, you can still participate in the class action. You may also choose to do nothing and remain an absent class member.
Impact on the World
The securities class action lawsuit against Regeneron Pharmaceuticals could have significant implications for the biotechnology industry as a whole. The lawsuit highlights the importance of transparency and full disclosure in the pharmaceutical industry, particularly in the face of increasing competition and regulatory scrutiny. It also underscores the potential risks associated with investing in biotech companies, particularly those with significant regulatory exposure.
Conclusion
If you purchased Regeneron Pharmaceuticals securities during the Class Period and believe you may be eligible to participate in the securities class action lawsuit, it is important to act quickly. The lead plaintiff deadline is March 10, 2025. Contact Rosen Law Firm for more information about the lawsuit and your potential eligibility to participate. The securities class action lawsuit against Regeneron Pharmaceuticals serves as a reminder of the importance of transparency and full disclosure in the pharmaceutical industry, particularly in the face of increasing competition and regulatory scrutiny.
For more information about the lawsuit or to discuss your potential eligibility, contact Rosen Law Firm at (866) 767-3653 or [email protected].
About Rosen Law Firm, P.A:
Rosen Law Firm, P.A. is a global investor rights law firm representing purchasers of securities, focusing on securities fraud class actions and shareholder derivative litigation. The firm was founded by Laurie Cooke in 2001. Since then, it has achieved landmark recoveries for investors, including the largest securities class action recovery in history.
